PureTech Health (LON:PRTC) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?

PureTech Health plc (LON:PRTC)’s share price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 123.09 and traded as low as GBX 117.80. PureTech Health shares last traded at GBX 119.92, with a volume of 1,297,591 shares trading hands.

Analyst Ratings Changes

Separately, Peel Hunt restated a “buy” rating and set a GBX 508 price target on shares of PureTech Health in a report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of GBX 508.

PureTech Health Trading Up 4.7%

The company has a debt-to-equity ratio of 6.33, a current ratio of 6.59 and a quick ratio of 2.51. The company has a market cap of £306.71 million, a price-to-earnings ratio of -2.74 and a beta of 0.77. The business’s fifty day moving average price is GBX 122.89 and its 200 day moving average price is GBX 124.63.

Insider Buying and Selling at PureTech Health

In related news, insider Robert Langer purchased 93,944 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was bought at an average price of GBX 1 per share, with a total value of £939.44. Also, insider Kiran Mazumdar Shaw acquired 93,944 shares of the stock in a transaction dated Wednesday, July 29th. The shares were bought at an average price of GBX 1 per share, with a total value of £939.44. Insiders purchased 617,569 shares of company stock worth $18,063,751 over the last 90 days. Company insiders own 13.41% of the company’s stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.